Original Article
Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency
N Engl J Med 2010; 363:355-364July 22, 2010
- Abstract
Background
The outcomes of gene therapy to correct congenital immunodeficiencies are unknown. We reviewed long-term outcomes after gene therapy in nine patients with X-linked severe combined immunodeficiency (SCID-X1), which is characterized by the absence of the cytokine receptor common γ chain.
Methods
The nine patients, who lacked an HLA-identical donor, underwent ex vivo retrovirus-mediated transfer of γ chain to autologous CD34+ bone marrow cells between 1999 and 2002. We assessed clinical events and immune function on long-term follow-up.
Results
Eight patients were alive after a median follow-up period of 9 years (range, 8 to 11). Gene therapy was initially successful at correcting immune dysfunction in eight of the nine patients. However, acute leukemia developed in four patients, and one died. Transduced T cells were detected for up to 10.7 years after gene therapy. Seven patients, including the three survivors of leukemia, had sustained immune reconstitution; three patients required immunoglobulin-replacement therapy. Sustained thymopoiesis was established by the persistent presence of naive T cells, even after chemotherapy in three patients. The T-cell−receptor repertoire was diverse in all patients. Transduced B cells were not detected. Correction of the immunodeficiency improved the patients' health.
Conclusions
After nearly 10 years of follow-up, gene therapy was shown to have corrected the immunodeficiency associated with SCID-X1. Gene therapy may be an option for patients who do not have an HLA-identical donor for hematopoietic stem-cell transplantation and for whom the risks are deemed acceptable. This treatment is associated with a risk of acute leukemia. (Funded by INSERM and others.)
Media in This Article
Figure 1
Vector Copy Numbers and T-Cell Subgroups after Gene Therapy.Figure 2
Serum Immunoglobulin Levels and Memory B-Cell Counts after Gene Therapy.Article Activity
- Article
The cytokine receptor common γ chain, which is encoded by the interleukin-2 receptor subunit gamma (IL2RG) gene, is a critical functional component of the receptors for interleukin-2, interleukin-4, interleukin-7, interleukin-9, interleukin-15, and interleukin-21.1 Naturally occurring mutations in IL2RG are responsible for X-linked severe combined immunodeficiency (SCID-X1) disease. This condition is characterized by the complete lack of T cells and natural killer cells, whereas B cells are present.2,3 Hematopoietic stem-cell transplantation is a lifesaving therapy. Despite associated improvements in the survival rate, however, non−HLA-identical hematopoietic stem-cell transplantation has a number of drawbacks. For example, reconstitution of T-cell function is delayed in patients receiving non−HLA-identical hematopoietic stem-cell transplants, as compared with patients receiving HLA-identical transplants; graft-versus-host disease (GVHD) requires post-transplantation immunosuppression (a therapy that is associated with high rates of infectious disease and death); and a decrease in thymopoiesis over the long term has been reported in some cases,4-7 although this outcome is not universal.6,8 We previously described the efficacy of ex vivo γ-chain retrovirus-mediated gene transfer into autologous hematopoietic precursor cells in five patients with SCID-X1, with a follow-up period of 2.5 years.9,10 Our results were consistent with those of a similar trial performed in London.11 Both groups reported the occurrence of leukemia (in 5 of 20 treated patients in the two studies combined), which was associated with oncogene transactivation by the vector's transcriptional control elements.12,13 Here, we describe the long-term outcomes (at 8 to 11 years) for patients treated in our center.
Methods
Nine patients with confirmed SCID-X1 who lacked an HLA-identical donor were eligible for enrollment in a γ-chain gene-therapy trial at the Necker−Enfants Malades Hospital between March 1999 and April 2002. An additional patient (Patient 9) was treated in Australia and described in a case report14 (see the Supplementary Appendix, available with the full text of this article at NEJM.org). The patients' genetically modified CD34+ bone marrow cells were prepared as described elsewhere.9,10
The protocol was approved by the French Drug Agency and the local investigational review board, and the study was conducted in accordance with the protocol. The patients' parents were informed that an alternative treatment based on hematopoietic stem-cell transplantation was available and that this new, experimental gene therapy carried a potential risk of leukemia. Written informed consent was obtained from the parents. All patients were placed in sterile isolation and received nonabsorbable antibiotics and anti-infective agents, including intravenous immune globulin. In Patient 3, the T-cell compartment10 was not reconstituted because of persistent splenomegaly (see the Supplementary Appendix). Clinical and immunologic investigations were subsequently performed at regular intervals. The end date for the analysis was March 1, 2010. The criterion for discontinuing intravenous immune globulin therapy was a combination of a T-cell count above 1000 per cubic millimeter and an absence of infection. Details of the study methods are included in the Supplementary Appendix.
Results
Clinical Outcome
Nine patients with γ-chain deficiency underwent gene therapy at a median age of 7 months (range, 1 to 11) (Table 1Table 1
Characteristics of the Patients.). The patients did not undergo a conditioning regimen. They received an infusion of autologous bone marrow−derived CD34+ cells transduced with the γ chain−containing retroviral vector (median dose of CD34+ γ-chain+ cells per kilogram of body weight, 4×106; range, 1×106 to 22×106).All treated patients left the sterile unit between days 45 and 90, and none subsequently had any severe opportunistic infections (see the Supplementary Appendix). Varicella−zoster virus (VZV) infections that did not require hospitalization developed in all patients and were not associated with severe adverse events. Patients 1, 2, and 7 had recurrent rhinitis. Skin manifestations of chronic human papillomavirus infection did not develop in any of the patients, although two patients had transient warts. Four patients (Patients 4, 5, 7, and 10) had the same severe adverse event (i.e., the development of T-cell acute lymphoblastic leukemia); the details of this outcome have been described previously.12 One of the four patients died, and the other three recovered after chemotherapy (Table 1 in the Supplementary Appendix). Immunoglobulin-replacement therapy was reinitiated in Patient 6, because of low antibody responses combined with recurrent otitis at 48 months, and in Patients 7 and 10, because of T-cell acute lymphoblastic leukemia and chemotherapy with the occurrence of bronchitis at 69 and 34 months, respectively. All patients had normal growth with respect to weight and height (Table 1) and attended regular schools. All patients except one did not have delays in their progression through school grades.
Vector Copy Number in T Cells versus B Cells
Longitudinal quantitative determination of the vector copy number revealed that in all patients, samples of T cells that were not blastic included approximately 0.5 to 1.5 copies per cell, with a seemingly stable pattern over time (Figure 1AFigure 1
Vector Copy Numbers and T-Cell Subgroups after Gene Therapy.). In contrast, the proportion of transduced B cells decreased from approximately 1.0% during the first 2 years to less than 0.1% 6 to 10 years after therapy10 (Table 2 in the Supplementary Appendix).T-Cell Reconstitution
T-cell counts reached normal values for age between 2 and 5 months after therapy. There was a trend (P=0.11) toward higher T-cell counts at 1 year after therapy in the patients in whom leukemia developed (Figure 1B). Flow-cytometric analysis of the patients' CD3+ population revealed γ-chain expression similar to that of control T cells9,10,12 (data not shown). Between 7.3 and 10.7 years after treatment, T-cell counts were within the normal range for age in six patients and were slightly below the normal range in one patient (Figure 1C and Table 2Table 2
Immunologic Characteristics at Last Follow-up.). The T-cell pool returned to normal values in the three survivors of leukemia (Patients 5, 7, and 10) 66 months, 37 months, and 14 months after completion of chemotherapy, respectively (Figure 1C and Table 2).T-Cell Characteristics
Long-Term Thymic Output
In all but one of the treated patients, analysis of the CD4+ T-cell subset showed that counts increased to the normal value for age during the first 2 years after therapy. In Patient 6, who received the lowest dose of transduced progenitor cells, CD4+ counts were below the normal range (Figure 1D). Over the long term (i.e., 7.3 to 10.7 years after treatment), CD4+ T-cell counts were within the normal range in four patients and slightly below the normal range in three patients. In Patient 1, CD4+ T-cell counts also decreased below the normal range 2 years after therapy but then stabilized. Up to 7.3 to 10.7 years after therapy, naive CD45RA+CD4+ T-cell counts were within the normal range in four patients and were low but detectable in three others (Patients 1, 6, and 7) (Figure 1E). Naive T cells were also measured by quantifying T-cell−receptor excision circles (TRECs). As shown in Figure 1F, levels of TRECs remained within the normal range except in Patient 6. These data correlated well with the CD31+CD45RA+CD4+ naive T-cell counts (Table 2). Naive T cells were newly detected after chemotherapy in the three survivors of leukemia, indicating a persistent potential for T-cell lymphopoiesis (Figure 1E and 1F and Table 2).
In all patients, CD8+ T-cell counts were within the normal range up to 7.3 to 10.7 years after therapy (Figure 1G). A balanced distribution between T-cell receptor αβ and T-cell receptor γδ was observed throughout the follow-up period (Table 2). Furthermore, natural killer T-cell counts in Patients 2, 6, 7, and 8 were within the normal range for age (Table 2). The other patients were not tested for this T-cell population. Moreover, 7 to 10 years after gene therapy, the proportion of CD4+, CD25+ high, forkhead box P3 (Foxp3+) T cells (a measure of the regulatory T-cell subgroup), assayed in Patients 2, 6, 8, and 10, was within the normal range (Table 2).
Repertoire Diversity of T-Cell−Receptors
Complementary determining region 3 (CDR3) length expression profiles (i.e., coding segments) for the 22 tested T-cell−receptor Vβ families showed a gaussian distribution in all patients (Fig. 1 in the Supplementary Appendix). Repertoire diversity returned in the survivors of leukemia, attesting to the persistence of transduced progenitor cells. The CDR3 length distribution for all 33 Vα families also showed a normal gaussian distribution in evaluated patients (Fig. 2 in the Supplementary Appendix). Finally, the Vγ and Vδ distribution in γδ T-cell populations strictly mirrored control values, with the predominance of Vγ9 Vδ2 cells (Fig. 3 in the Supplementary Appendix).
Long-Term Immune Function
Lymphocyte proliferation in response to phytohemagglutinin and anti-CD3 monoclonal antibodies was restored to normal levels in most patients 3 to 6 months after treatment and remained present throughout the follow-up period. Patient 6 had a mild decrease in T-cell proliferative capacity (Table 2, and Fig. 4A in the Supplementary Appendix). Patient 7 had discontinued chemotherapy 14 months before his cells were evaluated, making assessment of his immune function more difficult. Similarly, T-cell proliferation in response to at least one foreign antigen (tetanus toxoid, Candida albicans, VZV, or purified protein derivative) was positive in all tested patients (Patients 1, 2, 6, 7, 8, and 10) (Table 2).
Longitudinal Evolution of the Natural Killer–Cell Subgroup
Normal levels of natural killer cells (CD56+CD16+CD3− cells, which were found to express γ chain) were observed in the peripheral blood after gene therapy in patients who were 1 to 2 months of age.9 The counts remained stable for the first 18 months but decreased markedly thereafter (Table 2, and Fig. 4B in the Supplementary Appendix). Counts of natural killer cells increased to levels that were two to five times as high as baseline levels (to 150 to 250 cells per cubic millimeter) in Patients 4, 5, and 7 a few months before clonal T-cell proliferation, suggesting an expansion stimulated by the abnormal clone (Fig. 4B in the Supplementary Appendix).
B-Cell Antibody Responses
After gene therapy, B-cell counts, which were typically elevated at presentation in the infants with SCID-X1, decreased to normal values (Table 2). Although virtually no transduced B cells were detected in the blood of these patients 6 to 10 years after therapy, only three patients (Patients 6, 7, and 10) required immunoglobulin-replacement therapy to prevent bacterial infections. As shown in Figure 2Figure 2
Serum Immunoglobulin Levels and Memory B-Cell Counts after Gene Therapy., IgG serum levels were close to normal values in four patients, IgA levels were high or normal in five patients and low in two patients, and IgM levels were normal in seven of eight patients. Antibodies against polioviruses and tetanus and diphtheria toxoids were first detected at protective values 3 months after the third immunization in all patients except Patient 5. However, normal titers were not consistently detected in any of the tested patients at later time points, despite repeated immunization (Table 2 in the Supplementary Appendix); this was also the case for anti-VZV antibodies, which were not detected in five patients 3 to 6 years after varicella infection. A specific antibody response to polysaccharide antigens was detected after immunization against Streptococcus pneumoniae, with an increase in the titer in most patients that was more than four times as high as the titer before immunization; this elevated level persisted in three patients (Table 2 in the Supplementary Appendix). Isohemagglutinins also persisted in three of four patients tested (Table 2 in the Supplementary Appendix). A CD19+CD27+ memory B-cell subpopulation was present but constituted a small proportion of B cells (<10%) in all but one patient (Figure 2D) 7.3 to 10.7 years after therapy. The γ chain−dependent response to interleukin-21 was lacking in B cells from six tested patients as indicated by the lack of IgA production after stimulation by the CD40 ligand and interleukin-21 (Table 2 in the Supplementary Appendix). Furthermore, switched B cells (μ– δ– CD27+ B cells) were detected, albeit in low proportions, in Patients 2 and 5 (5% and 3%, respectively, vs. >10% in controls) but could not be detected in Patient 1.Integration Sites in Naive and Memory T Cells
We compared the diversity and abundance of integration sites in naive (CD45RA) and memory (CD45RO) CD4+ T cells obtained from Patient 2 at 102 months and from Patient 8 at 73 months. Pyrosequencing was used to determine 875 unique integration sites in Patient 2 and 2087 integration sites in Patient 8. There were no major differences between naive cells and memory cells in terms of overall diversity or distribution of integration sites (Fig. 5 in the Supplementary Appendix). The percentages of unique integration sites common to both naive and memory cells in Patients 2 and 8 were 21% and 13%, respectively. In Patient 2, an integration site within the CCND2 locus was abundant in naive cells (18%) but less so in memory cells (3%).
Discussion
We describe the long-term results of retrovirus-mediated gene therapy in nine patients with SCID-X1, with a median follow-up period of 9 years (range, 8 to 11). Common γ-chain gene transfer into autologous CD34+ cells led to sustained reconstitution of the T-cell pool and protection from infections, but at the risk of the development of T-cell acute lymphoblastic leukemia. All children except one, including the three survivors of T-cell acute leukemia, could live normally in a nonprotected environment and cope with microorganisms (e.g., VZV) without harmful consequences while growing normally. We documented the sustained presence of T cells (including the various effector and regulatory subgroups) with near-normal functional characteristics. Furthermore, the chemotherapy-induced immunodeficiency in the three survivors of leukemia resolved spontaneously without additional therapeutic intervention. These data provide strong evidence of the persistence of T-lymphocyte progenitors for at least 3 to 6 years after therapy. We noted some individual variability in T-cell reconstitution, which appeared to correlate strongly with the number of transduced cells injected and the diversity of integration sites within the T-cell pool.16 These data were consistent with a minimum required threshold for the number of injected, transduced cells of 1×106 to 3×106 CD34+ cells per kilogram.
There were no trends toward a decline in T-cell counts or loss of repertoire diversity over the follow-up period in most patients (see the Supplementary Appendix). T-cell reconstitution was similar to that seen in patients who have undergone hematopoietic stem-cell transplantation, in terms of phenotypic and functional characteristics. Six of seven patients with SCID-X1 had normal TREC levels 7.3 to 10.7 years after therapy; these values were similar to those observed 10 years after hematopoietic stem-cell transplantation in 9 of 11 surviving patients with SCID-X1.6
In contrast to the findings in the first few years after treatment,9,10 transduced B lymphocytes and myeloid cells were no longer detected 6 to 10 years after gene therapy, indicating that no transduced functional progenitors or stem cells persisted in the patients' bone marrow. Competition of a few transduced progenitors with untransduced stem cells could also be involved in B-cell development, since the γ-chain−negative B-cell lineage can be normally generated. However, the persistence of TREC+ naive T cells and their reappearance in patients who had undergone chemotherapy 3 to 6 years after gene therapy strongly suggest that T-cell progenitors persist and ensure sustained thymopoiesis. We speculate that these cells either commit to a T-cell lineage or maintain multipotency.17 Gene therapy for adenosine deaminase (ADA) deficiency has also been shown to restore T-cell counts and functions, with full restoration reported in five patients and partial restoration in another five patients.18 T-cell reconstitution in the latter patients was somewhat slower than that observed in our patients with SCID-X1. Furthermore, long-term T-cell counts appear to be somewhat lower in ADA-deficient patients. These data indicate that the quality of immune reconstitution depends on the genetic disease and the resulting physiological environment. We analyzed integration sites in sorted naive and memory T cells in two patients to assess and compare the potential effect of provirus integration on the capacity of these populations to proliferate or differentiate. Our data did not indicate deviation over time in clonal diversity or abundance. Integration patterns were similar in the two populations; this finding suggested an absence of selection bias and the maintenance of diversity in memory T cells. Overall, these results suggest that genome modification of T-cell precursors by means of retroviral insertion did not significantly skew T-cell differentiation, and they seem to argue against the hypothesis that vector insertion close to certain sets of genes favors the selection of clones that are more fit.16,19
All patients with SCID-X1 had a long-term (albeit incomplete) deficiency of natural killer cells. This finding mimics the long-term outcome of allogeneic hematopoietic stem-cell transplantation in patients with SCID-X1 in the absence of myeloablation4,5,7 and emphasizes that the conditions of this intervention do not favor the development and survival of natural killer cells as effectively as they do the T-cell lineage. Despite the lack of sustained transduced B-cell counts, four patients did not require immunoglobulin-replacement therapy. This outcome strongly suggests that in vivo B-cell immunity was preserved to some extent, as shown by the sustained presence of all serum immunoglobulin isotypes, detectable antibody responses to polysaccharide antigens (in some patients), and the presence of memory B cells with somatic mutations in their immunoglobulin-variable-region genes. These data may reflect the persistence of residual, transduced B cells that could not be detected in the blood, the ability of γ-chain−negative B cells to be activated by T-cell signals and cytokines (with the important exception of interleukin-21), or both.20-22
Overall, the present study confirms the expectation that ex vivo gene therapy for SCID-X1 can result in long-term correction of the SCID phenotype. However, the risk of the development of a malignant condition related to treatment, which involved the use of a retroviral vector containing a competent enhancer of long terminal repeats, cannot be ignored. Alternatives to gene therapy include transplantation from unrelated donors (who may not be identified for a considerable amount of time), from cord blood, or from haploidentical parents. With all three alternatives, GVHD and related infections remain a major cause of death. For instance, in our experience, after our gene-therapy protocol was closed in 2002, a total of 3 of 10 consecutive patients with γ-chain deficiency died from infections 2 to 4 months after undergoing haploidentical hematopoietic stem-cell transplantation; this survival rate is consistent with the 72% survival rate recently reported from the European database for SCID-X1.23 Our study showed substantial improvement of immune function in seven of nine patients treated with gene therapy; however, a potentially fatal treatment-related complication developed in four of the nine patients (44%), and one patient (11% of the total) died. Thus, gene therapy may be another option for patients with SCID-X1 who lack an HLA-identical donor. Our results set the stage for trials with safer vectors in the treatment of SCID-X1 and other severe forms of inherited diseases of the hematopoietic system.
Supported by grants from INSERM, Association Française contre les Myopathies (AT0203), the European Commission (QLK3-CT-1999-00859), the Concerted Safety and Efficiency Evaluation of Retroviral Transgenesis in Gene Therapy of Inherited Diseases (005242), Gene Therapy of Hematopoietic Stem Cells for Inherited Diseases (QLK3-CT-2001-00427), Agence Nationale de la Recherche (05-MRAR-004), Programme Hospitalier de Recherche Clinique of the Health Ministry (PHRC AOM 08064-P071204), Assistance Publique−Hôpitaux de Paris, Fondation de l'Avenir, Institut Pasteur and College de France, and the National Institutes of Health (AI52845 and AI082020, to Dr. Bushman). Dr. Hauer was supported by a scholarship from the Akademie der Naturforscher Leopoldina (BMBF-LPD 9901/8-149).
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Drs. Fischer and Cavazzana-Calvo contributed equally to this article.
We thank the families of the patients for their continuous support of the study, the medical and nursing staff of Unité d'Immunologie et d'Hématologie Pédiatriques, Hôpital des Enfants Malades for patient care, and M. Forveille for technical help.
Source Information
From the Department of Biotherapy (S.H.-B.-A., C.M., M.C.-C.), INSERM Unité 768 (S.H.-B.-A., J.H., F.R.-L., S.L., A.D., A.F., M.C.-C.), Centre d'Etude des Déficits Immunitaires (C.P.), and Pediatric Immuno-Hematology (M.D., J.L.C., S.B., A.D., A.F.), Necker−Enfants Malades Hospital; Clinical Investigation Center in Biotherapy, Groupe Hospitalier Universitaire Ouest, Assistance Publique–Hôpitaux de Paris (S.H.-B.-A., C.M., M.C.-C.); Paris Descartes University (S.H.-B.-A., C.P., J.L.C., S.B., A.F., M.C.-C.); Unité du Développement des Lymphocytes, Institut Pasteur and INSERM Unité 668 (A.L.); and the Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM Unité 550 (J.L.C.) — all in Paris; the Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia (G.P.W., F.D.B.); the Department of Family and Preventive Medicine, University of California, San Diego, School of Medicine, San Diego (C.C.B.); the Department of Infectious Diseases and Immunology, University Children's Hospital, Munich, Germany (B.H.B.); the Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans (L.L., R.S.); and the Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York (J.L.C.).
Address reprint requests to Dr. Hacein-Bey-Abina at the Department of Biotherapy, Necker−Enfants Malades Hospital, 149 rue de Sèvres, F-75015 Paris, France, or at salima.hacein-bey@nck.ap-hop-paris.fr.
- References
References
1
Sugamura K ,Asao H ,Kondo M , et al. The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol 1996;14:179-205
CrossRef | Web of Science | Medline2
Leonard WJ . Cytokines and immunodeficiency diseases. Nat Rev Immunol 2001;1:200-208
CrossRef | Web of Science | Medline3
Noguchi M ,Yi H ,Rosenblatt HM , et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993;73:147-157
CrossRef | Web of Science | Medline4
Buckley RH ,Schiff SE ,Schiff RI , et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999;340:508-516
Full Text | Web of Science | Medline5
Antoine C ,Muller S ,Cant A , et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003;361:553-560
CrossRef | Web of Science | Medline6
Cavazzana-Calvo M ,Carlier F ,Le Deist F , et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood 2007;109:4575-4581
CrossRef | Web of Science | Medline7
Neven B ,Leroy S ,Decaluwe H , et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 2009;113:4114-4124
CrossRef | Web of Science | Medline8
Sarzotti-Kelsoe M ,Win CM ,Parrott RE , et al. Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras. Blood 2009;114:1445-1453
CrossRef | Web of Science | Medline9
Cavazzana-Calvo M ,Hacein-Bey S ,de Saint Basile G , et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-672
CrossRef | Web of Science | Medline10
Hacein-Bey-Abina S ,Le Deist F ,Carlier F , et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002;346:1185-1193
Full Text | Web of Science | Medline11
Gaspar HB ,Parsley KL ,Howe S , et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004;364:2181-2187
CrossRef | Web of Science | Medline12
Hacein-Bey-Abina S ,Garrigue A ,Wang GP , et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118:3132-3142
CrossRef | Web of Science | Medline13
Howe SJ ,Mansour MR ,Schwarzwaelder K , et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008;118:3143-3150
CrossRef | Web of Science | Medline14
Ginn SL ,Curtin JA ,Kramer B , et al. Treatment of an infant with X-linked severe combined immunodeficiency (SCID-X1) by gene therapy in Australia. Med J Aust 2005;182:458-463
Web of Science | Medline15
Tanner JM . Normal growth and techniques of growth assessment. Clin Endocrinol Metab 1986;3:411-451
CrossRef16
Wang GP, Berry CC, Malani N, et al. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood 2010 March 12 (Epub ahead of print).
17
Weerkamp F ,Baert MR ,Brugman MH , et al. Human thymus contains multipotent progenitors with T/B lymphoid, myeloid, and erythroid lineage potential. Blood 2006;107:3131-3137
CrossRef | Web of Science | Medline18
Aiuti A ,Cattaneo F ,Galimberti S , et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;360:447-458
Full Text | Web of Science | Medline19
Baum C . Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol 2007;14:337-342
CrossRef | Web of Science | Medline20
Briere F ,Servet-Delprat C ,Bridon JM ,Saint-Remy JM ,Banchereau J . Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J Exp Med 1994;179:757-762
CrossRef | Web of Science | Medline21
Punnonen J ,Aversa G ,Cocks BG , et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci U S A 1993;90:3730-3734
CrossRef | Web of Science | Medline22
Avery DT ,Deenick EK ,Ma CS , et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 2010;207:155-171
CrossRef | Web of Science | Medline23
Gennery AR, Slatter MA, Grandin L, et al. Transplantation of haematopoietic stem cells and long term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol (in press).
- Citing Articles (56)
Citing Articles
1
David W. Scott, Jay N. Lozier. (2012) Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation. British Journal of Haematology 156:3, 295-302
CrossRef2
Laura DiNardo, Valerie Brown, Elena Perez, Nancy Bunin, Kathleen E. Sullivan. (2012) A single-center study of hematopoietic stem cell transplantation for primary immune deficiencies (PIDD). Pediatric Transplantation 16:1, 63-72
CrossRef3
Maria Karlsson, Wilfried Weber. (2012) Therapeutic synthetic gene networks. Current Opinion in Biotechnology
CrossRef4
Alice F Tarantal, Francesca Giannoni, C Chang I Lee, Jennifer Wherley, Teiko Sumiyoshi, Michele Martinez, Christoph A Kahl, David Elashoff, Stan G Louie, Donald B Kohn. (2012) Nonmyeloablative Conditioning Regimen to Increase Engraftment of Gene-modified Hematopoietic Stem Cells in Young Rhesus Monkeys. Molecular Therapy
CrossRef5
Luca Biasco, Cristina Baricordi, Alessandro Aiuti. (2012) Retroviral Integrations in Gene Therapy Trials. Molecular Therapy
CrossRef6
Christine Voelkel, Melanie Galla, Philip N. Dannhauser, Tobias Maetzig, Beate Sodeik, Axel Schambach, Christopher Baum. (2012) Pseudotype-Independent Nonspecific Uptake of Gammaretroviral and Lentiviral Particles in Human Cells. Human Gene Therapy120112071035000
CrossRef7
Mirjam Burg, Menno C. Zelm, Gertjan J. A. Driessen, Jacques J. M. Dongen. (2012) New frontiers of primary antibody deficiencies. Cellular and Molecular Life Sciences 69:1, 59-73
CrossRef8
James M. Wilson. (2012) It's Time for Gene Therapy to Get Disruptive!. Human Gene Therapy 23:1, 1-3
CrossRef9
Xiao-Xiang Zhang, Thomas J. McIntosh, Mark W. Grinstaff. (2012) Functional lipids and lipoplexes for improved gene delivery. Biochimie 94:1, 42-58
CrossRef10
Rebecca H. Buckley. (2012) The long quest for neonatal screening for severe combined immunodeficiency. Journal of Allergy and Clinical Immunology
CrossRef11
Anne Galy, Adrian J. Thrasher. (2011) Gene therapy for the Wiskott–Aldrich syndrome. Current Opinion in Allergy and Clinical Immunology 11:6, 545-550
CrossRef12
Dong H Hwang, Soo R Jeong, Byung G Kim. (2011) Gene transfer mediated by stem cell grafts to treat CNS injury. Expert Opinion on Biological Therapy 11:12, 1599-1610
CrossRef13
Chuanfeng Wu, Cynthia E. Dunbar. (2011) Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity. Frontiers of Medicine 5:4, 356-371
CrossRef14
Christopher Baum. (2011) Gene Therapy for SCID-X1: Focus on Clinical Data. Molecular Therapy 19:12, 2103-2104
CrossRef15
Claire Booth, H. Bobby Gaspar, Adrian J. Thrasher. (2011) Gene therapy for primary immunodeficiency. Current Opinion in Pediatrics 23:6, 659-666
CrossRef16
Michel Sadelain, Eirini P. Papapetrou, Frederic D. Bushman. (2011) Safe harbours for the integration of new DNA in the human genome. Nature Reviews Cancer
CrossRef17
Yesim Yilmaz-Demirdag. (2011) Should Newborns be Screened for Immunodeficiency? Lessons Learned from Infants with Recurrent Otitis Media. Current Allergy and Asthma Reports 11:6, 491-498
CrossRef18
C Brendel, U Müller-Kuller, S Schultze-Strasser, S Stein, L Chen-Wichmann, A Krattenmacher, H Kunkel, A Dillmann, M N Antoniou, M Grez. (2011) Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Therapy
CrossRef19
Attila A. Seyhan. (2011) RNAi: a potential new class of therapeutic for human genetic disease. Human Genetics 130:5, 583-605
CrossRef20
Samantha L Ginn, Ian E Alexander. (2011) Gene therapy: Progress in childhood disease. Journal of Paediatrics and Child Healthno-no
CrossRef21
Annette Deichmann, Martijn H Brugman, Cynthia C Bartholomae, Kerstin Schwarzwaelder, Monique MA Verstegen, Steven J Howe, Anne Arens, Marion G Ott, Dieter Hoelzer, Reinhard Seger, Manuel Grez, Salima Hacein-Bey-Abina, Marina Cavazzana-Calvo, Alain Fischer, Anna Paruzynski, Richard Gabriel, Hanno Glimm, Ulrich Abel, Claudia Cattoglio, Fulvio Mavilio, Barbara Cassani, Alessandro Aiuti, Cynthia E Dunbar, Christopher Baum, H Bobby Gaspar, Adrian J Thrasher, Christof von Kalle, Manfred Schmidt, Gerard Wagemaker. (2011) Insertion Sites in Engrafted Cells Cluster Within a Limited Repertoire of Genomic Areas After Gammaretroviral Vector Gene Therapy. Molecular Therapy 19:11, 2031-2039
CrossRef22
K. Kariko, H. Muramatsu, J. Ludwig, D. Weissman. (2011) Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Research 39:21, e142-e142
CrossRef23
Korashon Lynn Watts, Jennifer Adair, Hans-Peter Kiem. (2011) Hematopoietic stem cell expansion and gene therapy. Cytotherapy 13:10, 1164-1171
CrossRef24
Deborah J Accetta Pedersen, James Verbsky, John M Routes. (2011) Screening newborns for primary T-cell immunodeficiencies: consensus and controversy. Expert Review of Clinical Immunology 7:6, 761-768
CrossRef25
Megan M. Multhaup, Sweta Gurram, Kelly M. Podetz-Pedersen, Andrea D. Karlen, Debra L. Swanson, Nikunj V. Somia, Perry B. Hackett, Morton J. Cowan, R. Scott McIvor. (2011) Characterization of the Human Artemis Promoter by Heterologous Gene Expression In Vitro and In Vivo. DNA and Cell Biology 30:10, 751-761
CrossRef26
Marshall W Huston, Niek P van Til, Trudi P Visser, Shazia Arshad, Martijn H Brugman, Claudia Cattoglio, Ali Nowrouzi, Yuedan Li, Axel Schambach, Manfred Schmidt, Christopher Baum, Christof von Kalle, Fulvio Mavilio, Fang Zhang, Mike P Blundell, Adrian J Thrasher, Monique MA Verstegen, Gerard Wagemaker. (2011) Correction of Murine SCID-X1 by Lentiviral Gene Therapy Using a Codon-optimized IL2RG Gene and Minimal Pretransplant Conditioning. Molecular Therapy 19:10, 1867-1877
CrossRef27
Masayuki Kuroda, Hideaki Bujo, Masayuki Aso, Yasushi Saito. (2011) Adipocytes as a vehicle for ex vivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases. Journal of Diabetes Investigation 2:5, 333-340
CrossRef28
K Pike-Overzet, M Rodijk, Y-Y Ng, M R M Baert, C Lagresle-Peyrou, A Schambach, F Zhang, R C Hoeben, S Hacein-Bey-Abina, A C Lankester, R G M Bredius, G J A Driessen, A J Thrasher, C Baum, M Cavazzana-Calvo, J J M van Dongen, F J T Staal. (2011) Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer. Leukemia 25:9, 1471-1483
CrossRef29
Douglas R Higgs, James Douglas Engel, George Stamatoyannopoulos. (2011) Thalassaemia. The Lancet
CrossRef30
K. L. Shaw, D. B. Kohn. (2011) A Tale of Two SCIDs. Science Translational Medicine 3:97, 97ps36-97ps36
CrossRef31
H. B. Gaspar, S. Cooray, K. C. Gilmour, K. L. Parsley, F. Zhang, S. Adams, E. Bjorkegren, J. Bayford, L. Brown, E. G. Davies, P. Veys, L. Fairbanks, V. Bordon, T. Petropolou, C. Kinnon, A. J. Thrasher. (2011) Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction. Science Translational Medicine 3:97, 97ra80-97ra80
CrossRef32
H. B. Gaspar, S. Cooray, K. C. Gilmour, K. L. Parsley, S. Adams, S. J. Howe, A. Al Ghonaium, J. Bayford, L. Brown, E. G. Davies, C. Kinnon, A. J. Thrasher. (2011) Long-Term Persistence of a Polyclonal T Cell Repertoire After Gene Therapy for X-Linked Severe Combined Immunodeficiency. Science Translational Medicine 3:97, 97ra79-97ra79
CrossRef33
Erika Check Hayden. (2011) Gene-therapy successes spur hope for embattled field. Nature
CrossRef34
M. M. Hsieh, C. D. Fitzhugh, J. F. Tisdale. (2011) Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood 118:5, 1197-1207
CrossRef35
Jakub Tolar, Jennifer E Adair, Michael Antoniou, Cynthia C Bartholomae, Pamela S Becker, Bruce R Blazar, Juan Bueren, Thomas Carroll, Marina Cavazzana-Calvo, D Wade Clapp, Robert Dalgleish, Anne Galy, H Bobby Gaspar, Helmut Hanenberg, Christof Von Kalle, Hans-Peter Kiem, Dirk Lindeman, Luigi Naldini, Susana Navarro, Raffaele Renella, Paula Rio, Julián Sevilla, Manfred Schmidt, Els Verhoeyen, John E Wagner, David A Williams, Adrian J Thrasher. (2011) Stem Cell Gene Therapy for Fanconi Anemia: Report from the 1st International Fanconi Anemia Gene Therapy Working Group Meeting. Molecular Therapy 19:7, 1193-1198
CrossRef36
M. Reiss, I.C. Büttel, C.K. Schneider. (2011) Erfahrungsbericht aus dem Ausschuss für neuartige Therapien (CAT). Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 54:7, 822-830
CrossRef37
A. Liras. (2011) Induced human pluripotent stem cells and advanced therapies. Thrombosis Research 128:1, 8-13
CrossRef38
C. Walter, B. Rohde, D.C. Wicke, C. Pohler, A. Lührmann, H. Leyen. (2011) Regulatorischer Rahmen für neuartige Therapien. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 54:7, 803-810
CrossRef39
Marie W Pettit, Peter Griffiths, Paolo Ferruti, Simon CW Richardson. (2011) Poly(amidoamine) polymers: soluble linear amphiphilic drug-delivery systems for genes, proteins and oligonucleotides. Therapeutic Delivery 2:7, 907-917
CrossRef40
Douglas R. Kennedy, Brian J. Hartnett, Jeffrey S. Kennedy, William Vernau, Peter F. Moore, Thomas O’Malley, Linda C. Burkly, Paula S. Henthorn, Peter J. Felsburg. (2011) Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma. Veterinary Immunology and Immunopathology 142:1-2, 36-48
CrossRef41
H. Bönig, M. Heiden, J. Schüttrumpf, M.M. Müller, E. Seifried. (2011) Potenzial hämatopoetischer Stammzellen als Ausgangsmaterial für Arzneimittel für neuartige Therapien. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 54:7, 791-796
CrossRef42
Christopher Evans. (2011) Gene therapy for the regeneration of bone. Injury 42:6, 599-604
CrossRef43
Silvia Selleri, Immacolata Brigida, Miriam Casiraghi, Samantha Scaramuzza, Barbara Cappelli, Barbara Cassani, Francesca Ferrua, Memet Aker, Shimon Slavin, Alessia Scarselli, Caterina Cancrini, Sarah Marktel, Maria Grazia Roncarolo, Alessandro Aiuti. (2011) In vivo T-cell dynamics during immune reconstitution after hematopoietic stem cell gene therapy in adenosine deaminase severe combined immune deficiency. Journal of Allergy and Clinical Immunology 127:6, 1368-1375.e8
CrossRef44
Alain Fischer, Salima Hacein-Bey-Abina, Marina Cavazzana-Calvo. (2011) Gene therapy for primary adaptive immune deficiencies. Journal of Allergy and Clinical Immunology 127:6, 1356-1359
CrossRef45
E. B. de Oliveira-Junior, J. Bustamante, P. E. Newburger, A. Condino-Neto. (2011) The Human NADPH Oxidase: Primary and Secondary Defects Impairing the Respiratory Burst Function and the Microbicidal Ability of Phagocytes. Scandinavian Journal of Immunology 73:5, 420-427
CrossRef46
Grant D Trobridge. (2011) Genotoxicity of retroviral hematopoietic stem cell gene therapy. Expert Opinion on Biological Therapy 11:5, 581-593
CrossRef47
Christopher Baum. (2011) Prävention der Insertionsmutagenese. Unvermeidbar oder beherrschbar?. Pharmazie in unserer Zeit 40:3, 248-252
CrossRef48
Luigi Naldini. (2011) Ex vivo gene transfer and correction for cell-based therapies. Nature Reviews Genetics 12:5, 301-315
CrossRef49
M. Cavazzana-Calvo, A. Fischer, F. D. Bushman, E. Payen, S. Hacein-Bey-Abina, P. Leboulch. (2011) Is normal hematopoiesis maintained solely by long-term multipotent stem cells?. Blood 117:17, 4420-4424
CrossRef50
W. J. Bowers, X. O. Breakefield, M. Sena-Esteves. (2011) Genetic therapy for the nervous system. Human Molecular Genetics 20:R1, R28-R41
CrossRef51
Marta Claudia Frittoli, Erika Biral, Barbara Cappelli, Matilde Zambelli, Maria Grazia Roncarolo, Giuliana Ferrari, Fabio Ciceri, Sarah Marktel. (2011) Bone Marrow as a Source of Hematopoietic Stem Cells for Human Gene Therapy of β-Thalassemia. Human Gene Therapy 22:4, 507-513
CrossRef52
L. Brown, J. Xu-Bayford, Z. Allwood, M. Slatter, A. Cant, E. G. Davies, P. Veys, A. R. Gennery, H. B. Gaspar. (2011) Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Blood 117:11, 3243-3246
CrossRef53
Michael S D Kormann, Günther Hasenpusch, Manish K Aneja, Gabriela Nica, Andreas W Flemmer, Susanne Herber-Jonat, Marceline Huppmann, Lauren E Mays, Marta Illenyi, Andrea Schams, Matthias Griese, Iris Bittmann, Rupert Handgretinger, Dominik Hartl, Joseph Rosenecker, Carsten Rudolph. (2011) Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nature Biotechnology 29:2, 154-157
CrossRef54
Julia J.M. Eekels, Ben Berkhout. 2011. Toward a Durable Treatment of HIV-1 Infection Using RNA Interference. , 141-163.
CrossRef55
Francesca Ferrua, Immacolata Brigida, Alessandro Aiuti. (2010) Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Current Opinion in Allergy and Clinical Immunology 10:6, 551-556
CrossRef56
Peter E. Nielsen . (2010) Targeted Gene Repair Facilitated by Peptide Nucleic Acids (PNA). ChemBioChem 11:15, 2073-2076
CrossRef
